Urgent.News

the world's headlines, one feed

Editions

Business

PwC's US CEO thought fewer emails were better. Then he heard from employees.

PwC's Paul Griggs said he received feedback from employees who wanted to hear more about his decision-making process.

Abstract editorial illustration

PwC's US CEO, Paul Griggs, initially believed that fewer emails would be more effective. However, feedback from employees led him to reconsider his approach. Griggs, who has been with the firm for over three decades, admitted that he had been communicating less than his staff preferred. He realized he had a bias against excessive communication and had grown tired of lengthy emails.

To address this, Griggs began to simplify communication and slow it down. He understood that not everyone needs to agree with every decision, but they do need to comprehend the reasoning behind it. This realization led him to emphasize the importance of leadership and communication in his role. Griggs appreciated the firm's environment where leaders were open to changing their minds based on feedback.

He also learned that it's beneficial to share messages multiple times, using different styles and mediums. Despite initially being resistant to the idea of over-communication, Griggs now recognizes the value of frequent communication. He acknowledged that while he doesn't expect everyone to agree with every decision, understanding the rationale is crucial. This shift in his communication approach is part of his ongoing efforts to improve leadership and foster better understanding within the organization.

Written by urgent.news from Business Insider's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.

Read the original at businessinsider.com →

More in Business

Samsung Bioepis Files Korea’s First Keytruda Biosimilar Application

Domestic approval procedures have begun in earnest as companies move to gain an early foothold in the biosimilar market for Keytruda, the world’s biggest blockbuster drug with annual sales of 46…

  • Samsung Bioepis files first Keytruda biosimilar application in Korea.
  • SB27 biosimilar targets immuno-oncology treatments, developed by Merck.
  • Application covers 16 diseases, Samsung has 11 biosimilars in market.
Bain Capital set to acquire Gong Cha

Bain Capital set to acquire Gong Cha

Bain Capital a leading global private investment firm has agreed to acquire Gong cha Global one of the world s fastest growing tea brands from TA Associates and the company s other shareholders